Welcome to our dedicated page for Nemaura Med news (Ticker: NMRD), a resource for investors and traders seeking the latest updates and insights on Nemaura Med stock.
Nemaura Medical Inc. (NMRD) delivers innovative medical technology solutions focused on non-invasive health monitoring. This news hub provides investors and healthcare professionals with essential updates on the company's pioneering products like SugarBEAT glucose monitoring system and the Why Wait wellness platform.
Access all official announcements including regulatory milestones, partnership developments, and financial disclosures in one centralized location. Our curated feed features updates on clinical trial progress, manufacturing expansions, and strategic initiatives that shape Nemaura Medical's position in the diabetes care market.
Discover critical information about product launches, intellectual property updates, and leadership changes directly from corporate sources. For stakeholders tracking medical device innovation, this resource offers timely insights into Nemaura Medical's contributions to personalized healthcare solutions.
Bookmark this page for streamlined access to verified NMRD news. Check back regularly for updates on technological advancements and market developments from this forward-thinking medical technology company.
Nemaura Medical (Nasdaq: NMRD) announced securing $5 million in non-dilutive funding through a clean debt facility, deferring existing debt repayments for nine months. As of March 2022, the company reported a cash position of $17.7 million and a cash burn rate of $1.65 million per quarter. Nemaura aims to ramp up commercialization and form multiple large-scale partnerships. Revenue generation began in late 2021, with expectations to expand sales territories and revenue streams, particularly through their Miboko program.
Nemaura Medical (NASDAQ: NMRD) announced that CEO Dr. Faz Chowdhury will present virtually at the H.C. Wainwright Global Hybrid Investment Conference from May 23 – 26, 2022. The presentation is scheduled for May 24, 2022, available on demand starting at 7:00am ET. Dr. Chowdhury will discuss recent business developments and engage in one-on-one investor meetings. Nemaura specializes in wearable diagnostic devices, focusing on sugarBEAT®, a non-invasive glucose monitor, and the proBEAT™ system, integrating AI for diabetes management.
Nemaura Medical (Nasdaq: NMRD) announced that its UK licensee, MySugarWatch, is launching a direct-to-consumer campaign in Daily Mail to promote the sugarBEAT non-invasive continuous glucose monitor. The campaign targets over 1.2 million readers, aiming to enhance glucose management awareness. CEO Faz Chowdhury expressed confidence in supporting MySugarWatch's efforts to commercialize sugarBEAT, which is designed for diabetes management. The company is also advancing other products like proBEAT and Miboko.
Nemaura Medical (NASDAQ: NMRD) has announced that its UK licensee, MySugarWatch, has launched a significant awareness campaign for its sugarBEAT non-invasive glucose monitor. Targeting over 50,000 clinicians, the campaign commenced in April 2022 and includes advertisements in MIMS, a leading UK educational resource for physicians and pharmacists. CEO Faz Chowdhury expressed satisfaction with these commercialization efforts, highlighting the potential of sugarBEAT in aiding diabetes management. Nemaura is also advancing its products and programs focused on metabolic health.
Nemaura Medical announces that CEO Dr. Faz Chowdhury will present at the Planet MicroCap Showcase 2022, scheduled for May 4, 2022, at 9:00 AM Pacific Time. The event will be held at The Bally’s Hotel & Casino in Las Vegas, NV, from May 3-5, 2022. Dr. Chowdhury will also be available for one-on-one meetings. The company is focused on developing wearable diagnostic devices, including the sugarBEAT® continuous glucose monitor and the proBEAT™ AI-driven healthcare service. Nemaura aims to support diabetes management and monitoring of metabolic health through innovative technology.
Nemaura Medical, Inc. (NASDAQ: NMRD), a leader in wearable diagnostic devices, announces that CEO Dr. Faz Chowdhury will participate in the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. A corporate overview will be presented on March 28 at 9:00 a.m. ET, accessible to registered investors. The company is commercializing innovative products like sugarBEAT®, a continuous glucose monitor aimed at diabetes management, and proBEAT™, an AI-enhanced health service. Nemaura also launched Miboko, focusing on metabolic health, targeting a market projected to exceed $59 billion by 2025.
Nemaura Medical, Inc. (Nasdaq: NMRD) announced its third quarter fiscal 2022 results, marking its first-ever revenue recognition of $183,628 from sugarBEAT® CGM device shipments to MySugarWatch Limited. The company appointed Dr. Arash Ghadar as COO and launched a new metabolic health program, Miboko, leveraging its non-invasive glucose sensor technology. Despite recognizing revenue, total operating expenses were approximately $1.8 million, contributing to a decrease in cash reserves to about $23 million as of December 31, 2021.
Nemaura Medical (Nasdaq: NMRD) announced the appointment of Dr. Arash (Ash) Ghadar as Chief Operating Officer. With over 20 years of experience in the medical devices sector, Dr. Ghadar aims to enhance the company's manufacturing and distribution operations. His previous role at Datalink Electronics involved managing product development and operational oversight. Nemaura, focusing on non-invasive wearable diagnostic devices, is currently commercializing its glucose monitoring products, sugarBEAT® and proBEAT™, targeting the rapidly growing diabetes and wearable health-tech markets.
FAQ
What is the current stock price of Nemaura Med (NMRD)?
What is the market cap of Nemaura Med (NMRD)?
